These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32469065)

  • 61. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.
    Bairey O; Lebel E; Buxbaum C; Porges T; Taliansky A; Gurion R; Goldschmidt N; Shina TT; Zektser M; Hofstetter L; Siegal T
    Hematol Oncol; 2023 Dec; 41(5):838-847. PubMed ID: 37403752
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
    Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
    J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Residual diffusion-weighted imaging hyperintense signal in primary central nervous system lymphoma can predict early recurrence.
    Onishi S; Yamasaki F; Amatya VJ; Takayasu T; Yonezawa U; Taguchi A; Ozono I; Khairunnisa NI; Takeshima Y; Horie N
    J Neurooncol; 2023 Oct; 165(1):171-179. PubMed ID: 37831389
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
    Omuro AM; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2005 Jan; 64(1):69-74. PubMed ID: 15642906
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
    Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ
    Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
    Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma.
    Fu J; Ma X
    J BUON; 2021; 26(2):366-372. PubMed ID: 34076981
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
    Shimada K; Yamaguchi M; Atsuta Y; Matsue K; Sato K; Kusumoto S; Nagai H; Takizawa J; Fukuhara N; Nagafuji K; Miyazaki K; Ohtsuka E; Okamoto M; Sugita Y; Uchida T; Kayukawa S; Wake A; Ennishi D; Kondo Y; Izumi T; Kin Y; Tsukasaki K; Hashimoto D; Yuge M; Yanagisawa A; Kuwatsuka Y; Shimada S; Masaki Y; Niitsu N; Kiyoi H; Suzuki R; Tokunaga T; Nakamura S; Kinoshita T
    Lancet Oncol; 2020 Apr; 21(4):593-602. PubMed ID: 32171071
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
    Ostrowska B; Domanska-Czyz K; Romejko-Jarosinska J; Osowiecki M; Targonski L; Poplawska L; Konecki R; Kotarska M; Szymanski M; Borawska A; Swierkowska M; Dabrowska-Iwanicka A; Druzd-Sitek A; Paszkiewicz-Kozik E; Mroz-Zycinska E; Tajer J; Wojciechowska-Lampka E; Osiadacz W; Rymkiewicz G; Lapinska G; Wojewodzka-Mirocha M; Michalski W; Walewski J
    Br J Haematol; 2023 May; 201(4):663-672. PubMed ID: 36762710
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
    Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
    Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
    Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
    Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
    Fritsch K; Kasenda B; Schorb E; Hau P; Bloehdorn J; Möhle R; Löw S; Binder M; Atta J; Keller U; Wolf HH; Krause SW; Heß G; Naumann R; Sasse S; Hirt C; Lamprecht M; Martens U; Morgner A; Panse J; Frickhofen N; Röth A; Hader C; Deckert M; Fricker H; Ihorst G; Finke J; Illerhaus G
    Leukemia; 2017 Apr; 31(4):846-852. PubMed ID: 27843136
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
    Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
    Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Primary Central Nervous System Lymphoma in an Immunocompetent Young Adult Patient: A Rare Case.
    Wirdah A; Djamaludin N; Syahrir M; Andayani YD; Andriani M; Diansari Y
    Acta Med Indones; 2023 Jan; 55(1):107-109. PubMed ID: 36999259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.